Ipilimumab for advanced melanoma: let's not throw caution to the winds

Oncology (Williston Park). 2010 Dec;24(14):1296, 1299.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD*
  • CTLA-4 Antigen
  • Clinical Trials, Phase III as Topic
  • Humans
  • Immunotherapy
  • Ipilimumab
  • Melanoma / drug therapy*
  • Melanoma / mortality

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Ipilimumab